{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:37Z","timestamp":1747181197252,"version":"3.40.5"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:p>As per the American College of Obstetricians and Gynecologists in 2013, magnesium sulfate is the gold standard for the management of preeclampsia, but it has a short action time that does not provide stable maintenance of blood pressure. Labetalol is currently recommended as first-line treatment by the national UK guidance. This study included 355 pregnant Han Chinese women with preeclampsia and aimed to compare outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine. Women received 4\u2009g intravenous magnesium sulfate followed by the maintenance dose of 1\u2009g\/h intravenous magnesium sulfate (MS cohort, n = 104) or intravenous labetalol (LB cohort, n = 115), or oral nifedipine (NF cohort, n = 136). Therapy success: systolic blood pressure ~140\u2009mm Hg and diastolic blood pressure ~90\u2009mm Hg, therapy failure: persistent systolic blood pressure \u2265 160 or diastolic blood pressure \u2265 110\u2009mm Hg after maximum dosage of therapy (EL). Women of all cohorts successfully decreased systolic and diastolic blood pressures at EL as compared to them before therapy conditions (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, for all). At EL, systolic and diastolic blood pressures of women of the LB cohort decreased more than those of women of the MS and NF cohorts (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05, for all). Therapy was more successful in women of the LB cohort than those of the NF cohort (107 [93%] vs 112 [82%], <jats:italic toggle=\"yes\">P<\/jats:italic> = .0132). More numbers of women were reduced blood pressure after 1 day of therapy from the LB cohort than those of the NF (75 [65%] vs 21 [15%]) and MS (75 [65%] vs 35 [34%]) cohorts (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001 for both). Labetalol-induced tachycardia, bradycardia, and intracranial hemorrhage in pregnant women and respiratory distress syndrome and hypoglycemia in neonates. Intravenous labetalol provides proper reduction of blood pressure in Han Chinese women with preeclampsia but has the risk of undesirable maternal and neonatal adverse effects (Level of Evidence: IV; Technical Efficacy: Stage 4).<\/jats:p>","DOI":"10.1097\/md.0000000000035334","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T09:17:47Z","timestamp":1701163067000},"page":"e35334","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2625-4466","authenticated-orcid":false,"given":"Zhouli","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Beijing Shunyi Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jidong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Beijing Shunyi Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Beijing Shunyi Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Beijing Shunyi Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11906-017-0757-7","article-title":"Pathophysiology and current clinical management of preeclampsia.","volume":"19","author":"Amaral","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ijgo.14181","article-title":"A novel 12-hour versus 24-hour magnesium sulfate regimen in the management of eclampsia and preeclampsia in Ghana (MOPEP Study): a randomized controlled trial.","volume":"159","author":"Beyuo","year":"2022","journal-title":"Int J Gynaecol Obstet"},{"key":"R3-20250504","first-page":"1122","article-title":"Hypertension in pregnancy Report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy.","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R4-20250504","first-page":"CD000025","article-title":"Magnesium sulphate and other anticonvulsants for women with pre-eclampsia.","volume":"2010","author":"Duley","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20250504","first-page":"64","article-title":"Hamilton anxiety scale (HAMA) in infertile women with endometriosis and its correlation with magnesium levels in peritoneal fluid.","volume":"22","author":"Garaleji\u0107","year":"2010","journal-title":"Psychiatr Danub"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.3390\/ijerph20075418","article-title":"Psychological impact and women\u2019s evaluation of the first-trimester pre-eclampsia screening and prevention: ASPRE trial.","volume":"20","author":"Nik\u010devi\u0107","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/nu9050429","article-title":"The effects of magnesium supplementation on subjective anxiety and stress-A systematic review.","volume":"9","author":"Boyle","year":"2017","journal-title":"Nutrients"},{"key":"R8-20250504","first-page":"5062","article-title":"Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.","volume":"24","author":"Wu","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1055\/s-0038-1635109","article-title":"Genetic variation, magnesium sulfate exposure, and adverse neurodevelopmental outcomes following preterm birth.","volume":"35","author":"Clark","year":"2018","journal-title":"Am J Perinatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/HYPERTENSIONAHA.117.09972","article-title":"Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial.","volume":"70","author":"Webster","year":"2017","journal-title":"Hypertension"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e003624","DOI":"10.1161\/CIRCOUTCOMES.117.003624","article-title":"Personalizing the intensity of blood pressure control: modeling the heterogeneity of risks and benefits from SPRINT (systolic blood pressure intervention trial).","volume":"10","author":"Patel","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jcph.1685","article-title":"Clinical experiences of intravenous hydralazine and labetalol for acute treatment of severe hypertension in pregnant Thai women.","volume":"60","author":"Chera-Aree","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejogrb.2014.09.041","article-title":"Labetalol for hypertension during pregnancy and nipple pain.","volume":"182","author":"Rolfes","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"20220581","DOI":"10.1515\/biol-2022-0581","article-title":"Oral nifedipine and phytosterol, intravenous nicardipine, and oral nifedipine only: Three-arm, retrospective, cohort study for management of severe preeclampsia.","volume":"18","author":"Ma","year":"2023","journal-title":"Open Life Sci"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"441.e1","DOI":"10.1016\/j.ajog.2020.06.018","article-title":"Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure.","volume":"223","author":"Tolcher","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000117797","article-title":"Magnesium sulphate therapy in women with pre-eclampsia and eclampsia in Kuwait.","volume":"17","author":"Omu","year":"2008","journal-title":"Med Princ Pract"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10877-023-01006-4","article-title":"Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler.","volume":"37","author":"Mowafy","year":"2023","journal-title":"J Clin Monit Comput"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3892\/etm.2020.9406","article-title":"Effect of magnesium sulfate combined with labetalol on serum sFlt-1\/PlGF ratio in patients with early-onset severe pre-eclampsia.","volume":"20","author":"Wang","year":"2020","journal-title":"Exp Ther Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3390\/ijms22031038","article-title":"Racial disparity in drug disposition in the digestive tract.","volume":"22","author":"Gao","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"687.e1","DOI":"10.1016\/j.ajog.2017.08.018","article-title":"Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial.","volume":"217","author":"Sharma","year":"2017","journal-title":"Am J Obstet Gynecol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T08:01:44Z","timestamp":1746345704000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":21,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035334","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,11,17]]}}}